Objectives: Epidermal growth factor receptor (EGFR)-targeted therapies are a valid therapeutic option for advanced non-small-cell lung cancer (NSCLC), but unequivocally recognised predictive factors for therapeutic response are lacking. However, intrinsic resistance might occur due to loss of EGFR expression during the course of the disease or its treatment. Methods: Paraffin-embedded tissue from cases with metastatic NSCLC obtained at autopsy was retrieved from our archive. Specimens of primary tumour (n = 39; 64% adenocarcinoma) and of all corresponding metastases (n = 70) were immunohistochemically stained for EGFR expression. Two observers independently scored staining intensity and evaluated the percentage of positively stained cells. Identical staining intensity and 10% difference in number of stained cells were defined as perfect concordance; and one-increment difference in staining intensity and less than 30% difference in number of stained cells were defined as good concordance. Results: Twenty-seven out of 39 primary tumours (69%) were EGFR-positive on immunohistochemistry (IHC), with 12/27 (44%) of positive tumours exhibiting intense or moderate EGFR expression. The median number of EGFR-expressing cells in primary tumours was 50% (range 0-100%). Overall Spearman's rank correlations for staining intensity and percentage of positively stained cells between primary tumours and paired metastases were 0.78 ( p < 0.001) and 0.60 ( p < 0.001), respectively. Perfect concordance was observed in 51% (20/39) and good concordance in 18% (7/39) of corresponding pairs, respectively, whereas 9/12 metastases showing discordant staining with their corresponding primary tumours had lacked EGFR expression. Conclusions: In most NSCLCs, EGFR status of primary tumours correlates with EGFR status of corresponding metastases. Hence, loss of EGFR expression is unlikely during disease progression, local or non-EGFR-targeting systemic treatment. #
Introduction
Aberrant activity of epidermal growth factor receptor (EGFR), a potent receptor tyrosine kinase, represents one of the most frequent oncogenic insults causally incriminated in the tumourigenesis and malignant outgrowth of lung cancer and other human neoplasms [1] . In non-small-cell lung cancers (NSCLCs), this gain of EGFR activity is conveyed by multiple, mutually non-exclusive mechanisms, including overexpression of the receptor and its ligands, as well as by activating mutations in the receptor's intracellular tyrosine kinase domain [1] .
Accordingly, much emphasis has been devoted to the development of therapeutic approaches targeting aberrant EGFR activity: the addition of cetuximab, a monoclonal antibody targeting the EGFR extracellular domain, to standard chemotherapy results in moderate improvement of overall survival of patients with advanced NSCLC [2] . In preclinical model systems and other human neoplasms, overproduction of ligands, perturbations in signalling modules downstream of the EGFR and aberrant activation of other kinases have been associated with resistance to cetuximab; however, their predictive value for resistance to cetuximab in NSCLC remains to be defined [3] .
Treatment with small-molecule inhibitors of the EGFR tyrosine kinase domain such as gefitinib or erlotinib as single agents -rather than in combination with chemotherapyhas also been shown to prolong survival in patients with locally advanced or metastatic NSCLC [4] . NSCLCs with activating mutations of the EGFR kinase domain and/or EGFR gene amplification are particularly hypersensitive to these drugs; however, some patients with tumours expressing wildtype EGFR may also derive benefit from small-molecule EGFR inhibitors [5, 6] . Several mechanisms mediating intrinsic and acquired resistance, including secondary mutations of the EGFR kinase domain, mutations of K-RAS, amplification of the Met kinase and redistribution of another EGFR family kinase, ErbB3, have been associated with the clinical efficacy of these agents in patients with NSCLC, with additional mechanisms likely to be identified [7] [8] [9] [10] .
Importantly, it has been proposed that intrinsic resistance to EGFR-targeting agents may be due to a loss of EGFR expression in the primary tumour and/or the corresponding metastases in the course of disease evolution [3] . However, data on the concordance between EGFR expression in primary tumours and metastases are scant due to the limited use of invasive diagnostic procedures to determine the EGFR status in a given metastasis or to reassess EGFR status in primary tumours after failure of preceding treatment with chemotherapy and/or radiotherapy.
To determine the concordance of EGFR status between primary tumours and metastases in the course of disease or its treatment with non-EGFR-targeting therapies, we systematically assessed EGFR expression status on paired tissue material obtained at autopsy of patients with advanced NSCLC.
Materials and methods
Our cohort consisted of 39 autopsy cases with histopathologically proven NSCLC. The median (range) age at death was 66 (45-92) years. The most prevalent histological subtype was adenocarcinoma (64%, Table 1 ). Majority of cases were in pathological stage IV (85%). Twenty-five patients (64%) had received chemotherapy and/or radiotherapy. Two (5%) patients had relapsed with metastatic disease after prior surgery followed by adjuvant chemotherapy. None of the patients had been treated with EGFR-targeted therapy and 14 patients (36%) had received best supportive care only. Lymph node metastases were seen in 28 patients (72%; N1, 22; N2, 6). The liver was most frequently affected by distant metastases (28%), followed by the contra-lateral lung (23%) and adrenal gland (8%) ( Table 1) .
Paraffin-embedded tissue of primary tumour and all corresponding metastases were stained for EGFR expression by immunohistochemistry (IHC), using the Ventana EGFR 3C6 antibody according to the protocol provided by the manufacturer (Ventana Medical Systems, Inc., Tucson, AZ, USA). Two observers independently scored staining intensity on a semi-quantitative four-tiered grading scale (absent vs weak vs moderate vs intense) and evaluated the percentage of positively stained cells, according to the method described by Goldstein and Armin [11] .
As our data were not normally distributed (KolmogorovSmirnov p < 0.05), we used non-parametric tests. The degree of EGFR expression in primary tumours and metastases was compared by cross-table analysis. Spearman's rank correlation coefficients have been calculated for the assessment of overall concordance. For qualitative analysis, an identical staining intensity and 10% difference in number of staining cells were defined as a perfect concordance; a one-increment difference in staining intensity and less than 30% difference in number of staining cells were defined as a good concordance as opposed to no concordance. A p-value <0.05 has been considered as statistically significant. All calculations have been performed using the SAS software package. This study was conducted in accordance with Austrian legal regulations.
Results
In total, 27 of 39 primary tumours (69%) showed immunohistochemical EGFR-positivity, of which 44% showed intense or moderate EGFR staining. Representative staining results are shown in Fig. 1 . The median staining intensity of primary tumours was weak and the median (range) number of EGFR-expressing cells was 50 (0-100)%. Similarly, the median staining intensity was weak in both lymphatic and distant metastatic sites, except for one colon metastasis, showing strong EGFR staining intensity, and, conversely, one bone metastasis, which completely lacked EGFR staining. The median percentage of EGFR-positive cells varied considerably in various metastatic sites as it ranged from 10% (liver) to 100% (skin) ( Table 2) .
Both EGFR staining intensity and number of EGFR-positive cells showed considerable concordance between primary tumours and metastases; overall correlation coefficients for staining intensity and percentage of stained cells were 0.78 ( p < 0.001) and 0.60 ( p < 0.001), respectively. Perfect concordance was observed in 51% of corresponding pairs (20/39), and good concordance was found in 18% of pairs (7/39). However, in 12 of 39 cases (31%), no concordance was seen. Of those, nine (75%) had a relative loss of EGFR expression in metastases as compared to the primary tumour (Table 3) .
Discussion
Our data show that in post-mortem tissue EGFR expression in primary tumour correlates with the one observed in various metastatic sites. In more than two-thirds of cases, the concordance coefficient was 0.8 for EGFR staining intensity, and nearly 0.6 for the percentage of EGFR-positive cells. Thus, our results suggest that EGFR status of NSCLC remains largely unaltered during metastatic spreading.
To the best of our knowledge, this is the first systematic post-mortem investigation of primary NSCLC and corresponding metastases with respect to EGFR immunostaining. Previous reports describe findings in surgical biopsies/specimens, and their respective data differ considerably: Milas et al. [12] found a good concordance, while Italiano et al. [13] described a poor concordance between primary NSCLC and corresponding metastases, respectively. In a series of 11 NSCLC patients with bone metastases, 5/11 cases had a concordant EGFR expression pattern [14] . Conversely, in another study on 25 NSCLC patients, the concordance of EGFR expression between primary tumour and organ metastases was almost 90% [15] .
The discrepancy between our results and some of the biopsy-based reports might be explained by several methodological caveats. Studies using fine-needle biopsies are prone to sampling errors as only small areas of tumour tissue are evaluated, biasing the retrieved data on EGFR expression in both primary tumour and metastases. A general caveat of IHC-based studies is the variation between different antibodies with respect to staining results; a comparison between anti-EGFR antibodies from three companies showed different results in up to 24% [16] .
As we had sufficient amount of tumour tissue retrieved at autopsy from both primary tumour and metastases, our data should be considered largely free of sampling error. However, a limitation of our study is the relatively low number of cases. Furthermore, the presence of EGFR and K-RAS mutations has not been determined in our study. That the EGFR mutational status of primary NSCLC, as compared to EGFR immunostaining, was a more consistent predictor of benefit from EGFRtargeted therapy, has been confirmed by a recent study, which could also show that EGFR high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard IHC [17] .
However, data from the literature suggest that the mutational status of primary tumours be highly conserved in corresponding metastases as it has been shown that in cases of metastasising NSCLC, the concordance of both K-RAS and EGFR mutational status between primary tumour and metastases was over 72% (K-RAS 76-100% [14, 15, 18] ; EGFR 72-100% [15, 19, 20] ). Only one study showed a very poor concordance: mutations were identical in only 1/7 (14%) patients in case of EGFR and in 11/36 (31%) patients in case of KRAS [21] .
Clearly, only a part of tumour cells in the primary tumour and in the metastases expresses EGFR. Whether a selection of these cell populations exercised by EGFR-targeted therapies might contribute to therapy resistance, must be determined by future studies.
In conclusion, our data indicate that in NSCLC EGFR expression is highly correlated between primary tumour and metastases. Thus, loss of EGFR expression is unlikely during disease evolution, local or systemic treatment. In the light of these results, no further biopsy of metastases seems necessary if the evaluation of the primary tumour showed EGFR overexpression.
